SCHEMBL13847871

SCHEMBL13847871

Cc1cc(-c2nc(CCOc3ccc(CBr)c4sccc34)c(C)o2)cc(C)c1OP

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 0.57
PPARA Q07869 20/20 0.57
PPARD Q03181 5/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5759675 0.85 PPARG (0.72) PPARGPPARAPPARD
SCHEMBL13847868 0.84 PPARG (0.52) PPARGPPARAPPARD
SCHEMBL13847872 0.82 PPARG (0.46) PPARGPPARAPPARD
SCHEMBL6432402 0.76 PPARG (0.72) PPARGPPARAPPARD
SCHEMBL13524846 0.75 PPARG (0.55) PPARGPPARAPPARD
SCHEMBL2815935 0.75 PPARG (0.81) PPARGPPARAPPARD
SCHEMBL19711226 0.74 PPARG (0.74) PPARGPPARAPPARD
SCHEMBL5759298 0.73 PPARG (0.85) PPARGPPARAPPARD
SCHEMBL5741503 0.73 PPARG (0.70) PPARGPPARAPPARD
SCHEMBL5762327 0.73 PPARG (1.00) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131372-A1 PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES CHEN JAMES M 2009-05-21 US disclosed
US-7407965-B2 Phosphonate analogs for treating metabolic diseases GILEAD SCIENCES, INC. (US) 2008-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131372-A1 PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES PHOSPHO1, G6PC1, PC PPARG 314/4885PPARA 234/4885PPARD 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.